These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38750139)

  • 1. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
    Liang JH; Wu YF; Shen HR; Li Y; Liang JH; Gao R; Hua W; Shang CY; Du KX; Xing TY; Zhang XY; Wang CX; Zhu LQ; Shao YW; Li JY; Wu JZ; Yin H; Wang L; Xu W
    Leukemia; 2024 Jul; 38(7):1541-1552. PubMed ID: 38750139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA.
    Chen C; Di Y; Zhuang Z; Cai H; Jia C; Wang W; Zhao D; Wei C; Zhang W; Zhou D; Zhang Y
    J Cell Mol Med; 2024 Jul; 28(14):e18576. PubMed ID: 39054569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
    Wu FT; Lu L; Xu W; Li JY
    Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
    Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
    Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Li M; Ding N; Mi L; Shi Y; Du X; Yi Y; Yang L; Liu W; Zhu J
    Leuk Lymphoma; 2022 Mar; 63(3):608-617. PubMed ID: 34751093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
    Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
    Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 11. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
    Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
    Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
    Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study.
    Kim J; LE TM; Lee D; Nguyen HDT; Cho HJ; Sohn SK; Kim JG; Jeong SY; Ham JY; Jeong JY; Han HS; Moon JH; Baek DW
    In Vivo; 2024; 38(1):372-379. PubMed ID: 38148060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.
    Li JH; He ZQ; Lin FH; Chen ZH; Yang SY; Duan H; Jiang XB; Al-Nahari F; Zhang XH; Wang JH; Zhang GH; Zhang ZF; Li C; Mou YG
    Mol Cell Probes; 2019 Aug; 46():101411. PubMed ID: 31173881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
    Bobillo S; Crespo M; Escudero L; Mayor R; Raheja P; Carpio C; Rubio-Perez C; Tazón-Vega B; Palacio C; Carabia J; Jiménez I; Nieto JC; Montoro J; Martínez-Ricarte F; Castellvi J; Simó M; Puigdefàbregas L; Abrisqueta P; Bosch F; Seoane J
    Haematologica; 2021 Feb; 106(2):513-521. PubMed ID: 32079701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
    Alig S; Macaulay CW; Kurtz DM; Dührsen U; Hüttmann A; Schmitz C; Jin MC; Sworder BJ; Garofalo A; Shahrokh Esfahani M; Nabet BY; Soo J; Scherer F; Craig AFM; Casasnovas O; Westin JR; Gaidano G; Rossi D; Roschewski M; Wilson WH; Meignan M; Diehn M; Alizadeh AA
    J Clin Oncol; 2021 Aug; 39(23):2605-2616. PubMed ID: 33909455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
    Tabari E; Lovejoy AF; Lin H; Bolen CR; Lor Saelee S; Lefkowitz JP; Kurtz DM; Bottos A; Nielsen TG; Parreira JM; Luong KT
    Leuk Lymphoma; 2024 May; 65(5):618-628. PubMed ID: 38337191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.